BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Lundbeck Inc. Eyes Pipeline as Key Antidepressant Fades


5/3/2012 7:30:30 AM

Danish drugmaker Lundbeck missed first-quarter profit forecasts as it invests in new medicines to offset a faster-than-expected slide in sales of its top-selling antidepressant, which is losing patent protection. However, the firm said on Wednesday it was sticking to its full-year forecasts, arguing new drugs like Ebixa for Alzheimer's disease, as well as a string of soon-to-be launched treatments, would take up the slack. At 1105 GMT, Lundbeck shares were down 0.5 percent at 111.4 Danish crowns, lagging a 0.5 percent rise in the STOXX Europe 600 healthcare index. The shares have underperformed that index by about 20 percent over the past year.

Read at Reuters

Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES